Welcome Back

By becoming a RECADEMY member, you agree to site’s user

The MAT Factor

By Monica Oss, Chief Executive Officer, OPEN MINDS

Use of medication assisted treatment (MAT) for treating substance use disorders remains the exception and not the rule. Barriers to treatment include stigma, regulatory hurdles, few prescribers, expense, and limited availability (see Leveling The Playing Field and Addressing Addiction Stigma Among Clinicians: The Shatterproof ‘A Provider’s Pathway’ Curriculum).

But there has been a steady stream of research about the cost-effectiveness of MAT. A recent study—Medications For Opioid Use Disorder In County Jails—Outcomes After Release—added to that body of research.

In 2019, seven county correctional facilities in Massachusetts initiated pilot programs to provide all Food and Drug Administration (FDA)-approved medications for opioid use disorder (MOUD). The study cohort included 6,400 persons with probable OUD, with a split in those receiving MOUD or not.

The results were impressive. MOUD in jail was associated with a lower risk of overdoses, a lower risk of death by any cause, and a lower risk of reincarceration. It was also associated with improved post-release MOUD initiation. The incidence of hospitalizations did not differ substantially.

This new research adds to the growing body of evidence calling for continued evolution of SUD treatment best practices. And our team will continue to cover the new developments and new programs for treating SUD. For more, check out these resources in the OPEN MINDS Industry Library:

Strategic Perspectives

Executive Education

Program Profiles

Winning Proposals

Executive Resources

News

Market Insights

Want To Read More?

This content is exclusive to RECADEMY members.

RECADEMY is a comprehensive, research-based, online learning collaborative designed to provide critical information about emerging substance use disorder treatment topics and models of care.

Sign in or join the RECADEMY community for free today.